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  1） SH 582 （gestonorone caproate） was used in 11 cases of prostatic hypertrophy （7 in the
first or second stage， and 4 in the third・stage）．
  a） Subjective symptoms were improved in 6 cases and unchanged in 1 case with hypertrophy
of the first or．second stage．
  b） Residual urine volume was reduced ln 6 cases and unchanged in 1 case with hypertrophy
of the first or second stage． 1 one of the cases in the third stage showed any favorable change
in residual urine volumeL
  c） Strength of urinary flow was improved in 5 and unchanged in 2 cases with hypertrophy
of the first or second stage． None of the cases tn the third stage showed any irnprovement in
strength of urinary fiow．
  d） SH 582 is to be used for prostatic hypertrophy of the first or second stage． We thinlc
that it must be adniinistered at weekly doses of 400 mg for more than 3 months．
  e） There were no side－effects at all．
  2） SH 582， when administered to rats， did not produce such an atrophic change of the

























Table 1 Changes in clinical prostatism．
Patient F Diagnosis
Duration l Total dose of
of therapylhydroxypr． ogesterone
（Months） 1 （Gm）
Changes in clinical complaints
Frequency”’m－o－c－t－u－rl’a Forceless stream
Before］ After 1 Before l After I Before］ After
E．H． BPHinitial stage6 10．2 minimal］ none I severe 1 none 1 mild i mild
K．T．  BPH2nd． stage3 5，0 minimall none［ mild 1 mild iminimall none
1．Y．  BPH2nd． stage3 5．0 severe 1 severe 1 severe 1 severe 1 severe ［ severe
N．1．  BPH3rd． stage 6 10．2 severe 1 mild 1 severe 1 severe 1 severe i severe
S．N． BPHinitial stage3 5．0 mild 1 none 1 none 1 none 1 mild 1 none
     BPHS．K．    initi41 stage3 4．8 none！ none l mild 1 none lminimall none
s．s．   BPHinitial stage3 4．8 mild 1 none ［minimall none i none ［ none
Y．K． BPHinitial stage3 5．0 minimall none lminimall none lminimall none
N．Y．  BPH3rd． stage 3 5．0 severe 1 severe i severe 1 severe i severe 1 mild
J．1．  BPH3rd． stage 1 1．8 severe ］ severe 1 severe ！ severe 1 severe 1 severe
R．M．
I    BPH
Rrd． stage
1     1
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MF ： 2．s rn1／sec





























MF ： 1．s ml／sec
AF ： 1．2ml／sec
MF ： 12．！ ml／sec
－AF ： 12．3 ml／sec
MF ： ls．2ml／sec
AF ： 13．s ml／sec
MF ： ／s ml／sec
AF ： 13．sml／sec
MF ： 4．3ml／sec i MF ： 11．4ml／sec
AF ：2．gml／sec l AF ： 7．gml／sec
MF ： 2．sml／sec
AF ： 1．s rn1／sec
MF ： 1．oml／sec
AF ： 1．2 ml／sec
MF ： o．6ml／sec



























Table 2 Changes of clinical complaints







    Table 3 Results of residual urine
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Table 4 Results of uroflo皿etric examination





   1”一’
O i（2 cases： 6peration）
Volume Void ； Flow Time
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Fig．21 estrogen投与後dorsal lobe
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